Thrivent Financial for Lutherans’s Taysha Gene Therapies TSHA Stock Holding History

Thrivent Financial for Lutherans’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$98K	Buy	+14,520	New	+$85.9K	﹤0.01%	2578

Other funds holding TSHA

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Thrivent Financial for Lutherans's TSHA Position: Q2 2026 in Review

Thrivent Financial for Lutherans opened a new position in Taysha Gene Therapies (TSHA) in Q2 2026: 14,520 shares worth $98K. The stake represents ﹤0.01% of the portfolio and ranks #2578 among its holdings.

208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

Thrivent Financial for Lutherans held 14,520 shares of Taysha Gene Therapies worth $98K as of Q2 2026.
Taysha Gene Therapies was a new Thrivent Financial for Lutherans position in Q2 2026.
Taysha Gene Therapies made up ﹤0.01% of Thrivent Financial for Lutherans's portfolio in Q2 2026, its #2578 holding.
208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Thrivent Financial for Lutherans's 13F filing for Q2 2026, filed 14 Aug 2026.